You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.
The company's RT-PCR/MALDI-TOF test comprises five assays designed to detect the N, ORF1, and ORF1ab regions of the SARS-CoV-2 genome.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
Since the mutations are only found in a subset of patients' blood cells, the disorder, called VEXAS, might be treatable with a bone marrow transplant.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
The company's acquisitions of Thrive Early Detection and Base Genomics are meant to accelerate its development of a liquid biopsy multi-cancer screening test.
The funds will support continued growth in precision oncology, new product development, and new initiatives in the clinical trial and biopharmaceutical markets.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
Clinical test volume and requisitions received each grew about 2 percent year over year, while the average revenue per test fell 3 percent.
The reissued EUA expands the types of samples that may be used with the Broad Institute's PCR-based SARS-CoV-2 test, which was first authorized in July.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The firm's assay, dubbed MesoFind, uses an immunomagnetic capture method to identify surface antigens on mesothelioma pleural cells in a patient's blood sample.
For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.
The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
The test is designed to save resources by testing for the four viruses in one test using single nasopharyngeal, oropharyngeal, or nasal swab samples.
The reissued Emergency Use Authorization from the US Food and Drug Administration also permits the test's use in asymptomatic individuals, the firm said.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
Wren Laboratories and P23 Labs received revised EUAs that allow their previously authorized tests to now be used with new specimen types.
The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.
The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.
A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.
In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.